LivaNova (NASDAQ:LIVN) Updates FY 2026 Earnings Guidance

LivaNova (NASDAQ:LIVN) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 4.150-4.250 for the period, compared to the consensus estimate of 3.900. The company issued revenue guidance of $1.5 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on LIVN. Needham & Company LLC boosted their target price on LivaNova from $64.00 to $81.00 and gave the stock a “buy” rating in a report on Wednesday. Piper Sandler restated an “overweight” rating and issued a $85.00 price objective on shares of LivaNova in a research note on Thursday, February 19th. Wall Street Zen raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 20th. KeyCorp began coverage on shares of LivaNova in a report on Friday, December 19th. They issued an “overweight” rating and a $81.00 target price on the stock. Finally, Stifel Nicolaus set a $80.00 target price on shares of LivaNova in a research report on Wednesday. Seven research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $74.11.

LivaNova Price Performance

Shares of LivaNova stock traded up $0.41 during trading on Thursday, hitting $70.70. 162,400 shares of the company’s stock traded hands, compared to its average volume of 713,071. LivaNova has a twelve month low of $32.48 and a twelve month high of $71.92. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.33 and a quick ratio of 1.12. The firm’s fifty day moving average price is $64.41 and its 200 day moving average price is $58.81. The company has a market cap of $3.86 billion, a PE ratio of -17.77 and a beta of 0.97.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, February 25th. The company reported $0.86 EPS for the quarter, beating the consensus estimate of $0.80 by $0.06. The company had revenue of $360.86 million for the quarter, compared to the consensus estimate of $354.31 million. LivaNova had a negative net margin of 16.12% and a positive return on equity of 15.98%. The firm’s revenue for the quarter was up 12.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.81 EPS. LivaNova has set its FY 2026 guidance at 4.150-4.250 EPS. Analysts forecast that LivaNova will post 2.85 earnings per share for the current year.

LivaNova News Roundup

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: Q4 beat — LivaNova reported adjusted EPS of $0.86 vs. consensus $0.80 and revenue of $360.9M (up ~12% year-over-year), outpacing Street estimates. LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance
• Positive Sentiment: Raised FY‑2026 guidance — management now guides EPS $4.15–$4.25 versus consensus ~$3.90, signaling stronger expected profitability for the year. LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance
• Positive Sentiment: Analyst upgrade/price target lift — Needham raised its price target to $81 with a Buy rating, reflecting upside to the new guidance and margin outlook. LIVN PT Raised to $81 at Needham
• Positive Sentiment: Short interest dropped — short interest fell ~16.6% in February to ~2.03M shares (≈3.7% of float), lowering short-squeeze risk and supporting upside momentum.
• Neutral Sentiment: Growth outlook & product cadence — management outlined 6%–7% revenue growth for 2026 and highlighted core-business expansion plus an upcoming OSA launch that could drive medium-term growth. LivaNova outlines 6%–7% revenue growth for 2026
• Neutral Sentiment: Strategic data partnership — coverage discussed a data partnership with Orrum that could improve clinical evidence/positioning in cardiac care, but impact timing is unclear. Could LivaNova’s (LIVN) Data Partnership With Orrum Quietly Reshape Its Cardiac Care Narrative?
• Negative Sentiment: Profitability nuance — GAAP diluted EPS ($0.56) and a reported negative net margin (~16.1%) highlight remaining cost/one‑time items and indicate adjusted results still mask GAAP profitability pressures. LivaNova Q4 earnings snapshot / transcript

Hedge Funds Weigh In On LivaNova

Several large investors have recently bought and sold shares of the business. UMB Bank n.a. increased its position in shares of LivaNova by 22.6% during the fourth quarter. UMB Bank n.a. now owns 971 shares of the company’s stock worth $60,000 after acquiring an additional 179 shares in the last quarter. Parallel Advisors LLC raised its stake in shares of LivaNova by 28.8% in the 4th quarter. Parallel Advisors LLC now owns 1,266 shares of the company’s stock valued at $78,000 after purchasing an additional 283 shares during the period. California State Teachers Retirement System lifted its holdings in shares of LivaNova by 0.9% in the second quarter. California State Teachers Retirement System now owns 50,202 shares of the company’s stock valued at $2,260,000 after purchasing an additional 458 shares in the last quarter. EverSource Wealth Advisors LLC boosted its position in shares of LivaNova by 998.4% during the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after buying an additional 639 shares during the period. Finally, State of Wyoming bought a new position in shares of LivaNova during the second quarter worth about $31,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.